NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Verb Technology Company, Inc. (NASDAQ: VERB) from January 3, 2018 through May 2, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Verb investors under the federal securities laws.

To join the Verb class action, go to http://www.rosenlegal.com/cases-register-1617.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company did not have a contract with Oracle to jointly develop and market the Company’s product, notifiCRM; and (2) as a result, defendants’ statements about Verb’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 9, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1617.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

SOURCE: Rosen Law Firm PA

ReleaseID: 553569

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CannTrust Holdings Inc. (NYSE: CTST) from November 14, 2018 through July 5, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for CannTrust investors under the federal securities laws.

To join the CannTrust class action, go to http://www.rosenlegal.com/cases-register-1616.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) the Company’s Pelham greenhouse did not comply with certain regulations; (3) as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) as a result, defendants’ statements about CannTrust’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 9, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1616.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

SOURCE: Rosen Law Firm PA

ReleaseID: 553568

LATROBE, PA / ACCESSWIRE / July 26, 2019 / Commercial National Financial Corporation (OTCQX: CNAF)(Company), parent Company of Commercial Bank & Trust of PA, has reported results for the quarter ended June 30, 2019. The Company earned $1,032,000 (or $0.36 per average share outstanding) in the second quarter 2019 compared to $1,037,000 (or $0.36 per average share outstanding) in the second quarter of 2018. The Company earned $2,240,000 (or $0.78 per average share outstanding) for the six-month period ended June 30, 2019 and $2,077,000 (or $0.73 per average share outstanding) for the six-month period ended June 30, 2018.

The Company’s annualized return on average assets for the quarter ended June 30, 2019 was 0.98%, compared to 1.05% for the quarter ended June 30, 2018. The Company’s annualized return on average assets for the six-month period ended June 30, 2019 was 1.07% compared to 1.06% for the six-month period ended June 30, 2018. The Company’s very large AFS bond portfolio net unrealized market value gains, which represented 5.45% of book value at second quarter-end, have materially influenced ROA and ROE calculations thus far in 2019. Second quarter tax equivalent net interest margin was 4.03%. The effective tax rate for the quarter ended June 30, 2019 was 10.90% and the first six month effective tax rate was 8.70%. Tier one risk-based, total risk-based, leverage and common equity tier one capital ratios for June 30, 2019 were 22.05%, 22.57%, 14.01% and 22.05%, respectively.

The Company’s strong capital position, supplemented by recent and reasonably anticipated core earnings, remains supportive of the regular $0.26 quarterly common stock cash dividend payments to shareholders. Providing an attractive and reliable cash dividend income stream to all our shareholders through the safe and sound operation of the subsidiary bank is a long-standing top priority for the Company.

Direct and beneficial ownership by executive officers and directors of the Company’s outstanding shares totaled 472,975 shares, or 16.53% on June 30, 2019.

As disclosed each year in the Annual Report to Shareholders, on June 30, 2019, the Company employed 98 people in full-time and part-time positions. Forty-five (45) employees are represented by the United Auto Workers, Local 1799. Of that bargaining unit total, Thirty-five (35) employees are full-time and ten (10) employees are part-time. The Company has had unionized employees since 1972. In October 2018, the agreement between the Company and the bargaining unit was negotiated and subsequently ratified by the bargaining unit with an effective date of February 16, 2019. The labor agreement will expire in February 2024. The Commonwealth of Pennsylvania and the National Labor Relations Board both afford protection to the organized status of pre-existing collective bargaining units. The Company has been advised that bargaining unit status may limit the Company’s strategic options relative to those of non-unionized insured depository institutions. The Company continues to consider this as a factor in its strategic and capital management decisions.

The Company operates nine community banking facilities in Greensburg, Hempfield Township, Latrobe, Ligonier, North Huntingdon, Unity Township and West Newton, Pennsylvania and also maintains a commercial business development sales force throughout its entire market area. The Company operates an asset management and trust division of Commercial Bank & Trust of PA headquartered in Greensburg, Pennsylvania. Commercial Bank & Trust of PA also serves its customer base from an Internet banking site (www.cbthebank.com) and an automated TouchTone Teller banking system.

Safe Harbor Statement

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. These statements are based on information currently available to the Company, and the Company assumes no obligation to update these statements as circumstances change. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including changes in general economic and financial market conditions, unforeseen credit problems, and the Company’s ability to execute its business plans. The actual results of future events could differ materially from those stated in any forward-looking statements herein.

Contact Information:
Wendy S. Piper
First Senior Vice President
Secretary/Treasurer
wpiper@cbthebank.com
724-537-9923

COMMERCIAL NATIONAL FINANCIAL CORPORATION
CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION
(Unaudited)
(Dollars in thousands, except per share data)

June 30,

December 31

June 30,

2019

2018

2018

ASSETS

Cash and due from banks on demand

$
4,730

$
5,642

$
5,017

Interest bearing deposits with banks

2,081

59

65

Total cash and cash equivalents

6,811

5,701

5,082

Securities available for sale

162,326

159,741

165,791

Restricted investments in bank stock

1,656

1,411

1,278

Loans

230,469

227,747

212,768

Allowance for loan losses

(1,374
)

(1,349
)

(1,289
)

Net loans

229,095

226,398

211,479

Premises and equipment

2,756

2,800

2,943

Investment in Life Insurance

20,034

19,767

19,493

Other assets

3,792

3,808

4,003

Total assets

$
426,470

$
419,626

$
410,069

LIABILITIES AND SHAREHOLDERS’ EQUITY

Liabilities:

Deposits:

Non-interest bearing

$
128,333

$
128,437

$
119,561

Interest bearing

188,714

197,482

196,677

Total deposits

317,047

325,919

316,238

Short-term borrowings

41,684

32,822

34,338

Other liabilities

2,622

1,351

877

Total liabilities

361,353

360,092

351,453

Shareholders’ equity:

Common stock, par value $2 per share; 10,000,000 shares authorized; 3,600,000 shares issued; 2,860,953 shares outstanding in 2019 and 2018

Common stock, par value $2 per share; 10,000,000 shares authorized; 3,600,000 shares issued; 2,860,953 shares outstanding in 2019 and 2018

7,200

7,200

7,200

Retained earnings

63,838

63,085

62,305

Accumulated other comprehensive (loss) income

6,623

1,793

1,655

Less treasury stock, at cost, 739,047 shares in 2019 and 2018

(12,544
)

(12,544
)

(12,544
)

Total shareholders’ equity

65,117

59,534

58,616

Total liabilities and shareholders’ equity

$
426,470

$
419,626

$
410,069

COMMERCIAL NATIONAL FINANCIAL CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(Dollars in thousands, except per share data)

Three Months

Six Months

Ended June 30

Ended June 30

2019

2018

2019

2018

(unaudited)

(unaudited)

(unaudited)

(unaudited)

INTEREST INCOME:

Interest and fees on loans

$
2,582

$
2,255

$
5,173

$
4,485

Interest and dividends on securities:

Taxable

1,047

1,098

2,098

2,137

Exempt from federal income taxes

538

506

1,097

974

Other

29

16

63

28

Total Interest income

4,196

3,875

8,431

7,624

INTEREST EXPENSE:

Interest on deposits

190

125

377

226

Interest on short-term borrowings

257

115

509

172

Total Interest expense

447

240

886

398

NET INTEREST INCOME

3,749

3,635

7,545

7,226

PROVISION FOR LOAN LOSSES

–

–

–

–

NET INTEREST INCOME AFTER

PROVISION FOR LOAN LOSSES

3,749

3,635

7,545

7,226

OTHER OPERATING INCOME:

Asset management and trust income

331

321

671

677

Service charges on deposit accounts

185

185

354

362

Net Security losses

(4
)

–

(7
)

–

Gain on sale of OREO

–

–

4

–

Income from investment in life insurance

124

120

250

247

Other income

36

50

100

129

Total other operating income

672

676

1,372

1,415

OTHER OPERATING EXPENSES:

Salaries and employee benefits

1,906

1,796

3,773

3,626

Net occupancy expense

202

210

420

427

Furniture and equipment

108

58

214

180

Pennsylvania shares tax

142

142

284

270

Legal and professional

97

114

175

234

FDIC insurance expense

28

27

56

56

Other expenses

780

809

1,543

1,532

Total other operating expenses

3,263

3,156

6,465

6,325

INCOME BEFORE INCOME TAXES

1,158

1,155

2,452

2,316

Income tax expense

126

118

212

239

Net income

$
1,032

$
1,037

$
2,240

$
2,077

Average Shares Outstanding

2,860,953

2,860,953

2,860,953

2,860,953

Earnings Per Share

$
0.36

$
0.36

$
0.78

$
0.73

SOURCE: Commercial National Financial Corporation

ReleaseID: 553573

SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that the Company’s wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals, Inc. (“Napo”), is hosting a Facebook Live conversation at 3 p.m. Eastern time today, July 26, 2019, between Josh Robbins and Murray Penner, who serves as Executive Director, North America for the Prevention Access Campaign. The discussion can be viewed on Napo’s Facebook page, facebook.com/napopharma.

Prevention Access Campaign is a health equity initiative to end the dual epidemics of HIV and HIV-related stigma by empowering people with and vulnerable to HIV with accurate and meaningful information about their social, sexual, and reproductive health.

Today’s Facebook Live discussion is the second event in the monthly “HIV Community Conversations presented by Napo Pharmaceuticals” series, which brings key advocates and activists in the HIV community together to talk about the issues that matter most to people living with and affected by HIV/AIDS. The series premiered last month with a Facebook Live conversation about HIV Long-Term Survivor’s Day between Josh Robbins and Tez Anderson, the founder of Let’s Kick ASS - AIDS Survivor Syndrome, a grassroots movement empowering HIV Long-Term Survivors to thrive.

Josh Robbins is an HIV/AIDS activist, blogger, writer, social media marketer, and a consultant to Napo. His work has been featured on The Advocate, Human Rights Campaign, Healthline, POZ and a myriad of additional publications. Robbins was named to the POZ 100 List in 2013.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.

About Mytesi®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc

ReleaseID: 553563

NOTTINGHAM, ENGLAND / ACCESSWIRE / July 26, 2019 / Asmodee Entertainment is delighted to announce that Aconyte, the newly announced fiction imprint of global games giant Asmodee, have entered into a distribution agreement with Simon & Schuster for the US and Canadian book trades. The well-known publishing house will handle sales and distribution throughout North America starting with Aconyte’s very first releases, due on shelves in late spring 2020.

Michael Perlman, Vice President, General Manager, Simon & Schuster Distribution Services said: “We are delighted to welcome Aconyte Books to our family to distribution clients. We look forward to helping their publishing program grow.”

Aconyte’s publisher Marc Gascoigne said: “We’re very pleased with this new partnership. Aconyte’s primary mission is to create spectacular thrillers and fantasy novels based around the most deeply realized of our game worlds – Arkham Horror, Legend of the Five Rings, Pandemic, Descent and Catan, to name just a few. With their impressive track record handling tie-in books based on world-famous properties, Simon & Schuster are the ideal partners to help launch our novels into the North American book trade.”

About Simon & Schuster

Simon & Schuster, a part of CBS Corporation, is a global leader in general interest publishing, dedicated to providing the best in fiction and non-fiction for readers of all ages, and in all printed, digital and audio formats. Its distinguished roster of authors includes many of the world’s most popular and widely recognized writers, and winners of the most prestigious literary honors and awards. It is home to numerous well-known imprints and divisions such as Simon & Schuster, Scribner, Atria Books, Gallery Books, Pocket Books, Free Press, Adams Media, Simon & Schuster Children’s Publishing, and Simon & Schuster Audio and international companies in Australia, Canada, India, and the United Kingdom. Simon & Schuster proudly brings the works of its authors to readers in more than 200 countries and territories. For more information, visit simonandschuster.com.

About Aconyte

Aconyte was announced in April 2019 and their first books will be published in late spring 2020. The imprint’s mission is to adapt the deepest, most imaginative of Asmodee’s game worlds into novels. Based in Nottingham, UK, they also have staff in several US locations. They are a part of Asmodee’s Entertainment platform, a division of the global games publisher and distributor expressly working to take the group’s best intellectual properties into new formats. Learn more at aconytebooks.com.

About Asmodee

Asmodee Group is a leading international games publisher and distributor committed to telling amazing stories through great games with over 34 million games sold in more than 50 countries. Through our portfolio of iconic game titles, including Catan, Ticket to Ride, Pandemic, Dead of Winter, Splendor, KeyForge, Dobble/Spot it! and Star Wars: X-Wing, we create a dynamic transmedia experience for players across a variety of digital and physical platforms. Asmodee also creates inspiring and innovative products in partnership with leading entertainment and technology companies. Asmodee operates in Europe, North America, South America and Asia and is headquartered in Guyancourt, France. Learn more at corporate.asmodee.com.

Press Contacts

More information at aconytebooks.com or email contact@aconytebooks.com

SOURCE: Aconyte Books

ReleaseID: 553389

CALGARY, AB / ACCESSWIRE / July 26, 2019 / Pacific Iron Ore Corporation (TSX-V: POC) announces that it has filed its Financial Statements and Management Discussion and Analysis for the six months ended June 30, 2019. These documents are now available on SEDAR.

2019 Second Quarter Results

During the first six months of 2019 the Corporation incurred a net loss of $67,265 or ($0.01) per common share as compared to a net loss of $200,760 or ($0.03) per common share in the first six months of 2018.

Its major expenses incurred in the six-month period included:

Operating expenses totaled $34,735 in 2019 as compared to $48,042 in 2018, a decrease of $13,307.

Mineral property acquisition costs and exploration costs expensed in 2019 totaled $4,862 as compared to $22,604 in 2018.

General and administrative expenses totaled $30,291 in 2019 as compared to $128,608 in 2018, a decrease of $98,317.

Net financial (expenses) income during the period totaled ($2,623) as compared to $1,506 in the prior period. Financial income consists of interest earned on invested cash deposits and unrealized gains or losses on marketable securities. Cash deposits are comprised solely of bank investment certificates with a maturity date of less than three months and are on deposit with a Canadian Chartered Bank. Financial expenses are comprised interest and bank charges, fair value adjustments on assets held for sale and accruals for Part XII taxes.

Liquidity – At June 30, 2019 Cash and short-term deposits totaled $311,905 and working capital was $295,972 for the current period.

Appointment of Director

Pacific Iron Ore Corporation is pleased to announce that Mr. Binyomin Posen of Toronto, Ontario has joined the Board of Directors of the company.

Mr. Posen is a Senior Analyst at Plaza Capital, where he focuses on corporate finance, capital markets and helping companies go public. After three and a half years of studies overseas, he returned to complete his baccalaureate degree in Toronto. Upon graduating (on the Dean’s List) he began his career as an analyst at a Toronto boutique investment bank where his role consisted of raising funds for IPOs and RTOs, business development for portfolio companies and client relations. The appointment is subject to TSX-V approval.

Company Contacts:

For further information please refer to the Corporations profile on SEDAR which can be accessed at www.sedar.com or contact:

R. A. N. Bonnycastle, Chief Executive Officer
Telephone: (403) 269-6795
Facsimile: (403) 265-2887

Forward Looking Statements:

The TSX.V Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This release includes certain statements that may be deemed “forward looking statements”. All statements in this release, other than statements of historical facts that address future production, reserves potential, exploration drilling, exploration activities and events or developments that the Corporation expects are forward looking statements. Although the Corporation beliefs the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause results to differ materially from those in the forward looking statements include, but are not limited to: market prices; exploitation and exploration successes; continued availability of capital, financing and personnel; government regulation and laws; the Corporations relationship with First Nations; environmental developments; and general economic, market or business conditions. Investors are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those projected in the forward-looking statements. For more information on Pacific Iron Ore Corporation, Investors should review the Corporation’s registered filings which are available at www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provide (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Pacific Iron Ore Corporation

ReleaseID: 553565

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Diebold Nixdorf, Inc. (NYSE: DBD) from May 4, 2017 through July 4, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Diebold investors under the federal securities laws.

To join the Diebold class action, go to http://www.rosenlegal.com/cases-register-1615.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing delays in systems rollouts as well as a longer customer decision-making process and order-to-revenue conversion cycle; (2) the foregoing issues were negatively impacting the Company’s services business and operations; and (3) as a result, defendants’ statements about Diebold’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 3, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1615.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

SOURCE: Rosen Law Firm PA

ReleaseID: 553567

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

A. O. Smith Corporation (NYSE: AOS)
Class Period: July 26, 2016 to May 16, 2019
Lead Plaintiff Deadline: July 29, 2019

Throughout the class period, A. O. Smith Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) A.O. Smith had undisclosed business connections and entanglements with UTP through which it funneled up to 75% of its China product sales; (b) A.O. Smith had used UTP to engage in channel stuffing by artificially inflating inventories purportedly sold through distributors that were not based on consumer demand, thereby approximately doubling the normal level of inventory at such distributors; (c) A.O. Smith had used its UTP relationship to artificially inflate the sales figures it reported to investors by as much as 8% and to conceal worsening sales trends that the Company was experiencing in China; (d) A.O. Smith’s sales growth had been primarily in lower margin products as its higher priced products were being undercut by competition in “second-tier” Chinese cities, causing the Company to experience significant margin pressures; (e) A.O. Smith had increased its cash reserves in China to over $530 million in furtherance of its channel stuffing and sales manipulation scheme, encumbering the Company’s ability to repatriate the cash or use it for capital expenditures; and (f) as a result of (a)-(e) above, A.O. Smith’s business, operations, and prospects were significantly worse than publicly represented and the Company was poised for sales and earnings declines in China, its most important international market.

Learn about your recoverable losses in AOS: http://www.kleinstocklaw.com/pslra-1/a-o-smith-corporation-loss-submission-form?id=2620&from=1

Eros International Plc (NYSE: EROS)
Class Period: July 28, 2017 to June 5, 2019
Lead Plaintiff Deadline: August 20, 2019

The complaint alleges that throughout the class period Eros International Plc made materially false and/or misleading statements and/or failed to disclose that: (1) Eros and its executives engaged in a scheme to use related-party
transactions to fabricate receivables that they reported in Eros’s public financial disclosures; (2) because of this scheme, Eros’s financial position was weaker than what the Company disclosed; (3) consequently, the Company’s Indian subsidiary, Eros International Media Ltd (“EIML”), missed loan payments and had its credit
downgraded; and (4) due to the foregoing, Defendants’ statements about Eros’s receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in EROS: http://www.kleinstocklaw.com/pslra-1/eros-international-plc-loss-submission-form?id=2620&from=1

Netflix, Inc. (NASDAQGS: NFLX)
Class Period: April 17, 2019 to July 17, 2019
Lead Plaintiff Deadline: September 20, 2019

According to the complaint, Netflix, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in NFLX: http://www.kleinstocklaw.com/pslra-1/netflix-inc-loss-submission-form?id=2620&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 553566

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Intelligent Systems Corporation (NYSE American: INS) from January 23, 2019 through May 29, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Intelligent Systems investors under the federal securities laws.

To join the Intelligent Systems class action, go to http://www.rosenlegal.com/cases-register-1599.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Defendant Petit, the “financial expert” on Intelligent Systems’ Audit Committee engaged in accounting fraud as the CEO of MiMedx Group, Inc.; (2) Intelligent Systems’ CEO, Defendant Strange, engaged in undisclosed related-party transactions with Defendant Petit and others and had an undisclosed personal relationship with the Company’s auditor; (3) Intelligent Systems had its employees set up or take control of shell companies in Asia so they could partake in undisclosed related-party transactions for the purpose of either fabricating revenue for the Company and/or siphoning money out of the Company; and (4) as a result, defendants’ statements about Intelligent Systems’ business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 9, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1599.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

SOURCE: Rosen Law Firm PA

ReleaseID: 553564